For individuals with a specific allergy to Hymenoptera bites, the venom immunotherapy (VIT) may be a relatively effective treatment option. Treatments failures do however occur and VIT may cause frequent systemic allergic side effects, mainly in honeybee venom allergy persons. The Immunotherapy is expensive and time consuming. New strategies to improve safety and efficacy of this treatment are therefore of general interest. We propose here a systematic approach to study the basic and biotechnological problems related with the development of safe formulations of bee venoms within liposomes to be used in VIT. Liposomes could increase the immunogenic capacity, decrease the toxicity and decrease the quantity and frequency of the venom doses during the VIT. However, bee venom mellitin and phospholipase destruct the phospholipid membranes. Our central idea^® in modifying the VIT is the combination of three different tools: encapsulation of chemically modified venoms within stabilized liposomes.Here we present the results of the interaction of modified bee venom (BVm) with artificial membranes.